Pharmeasy Unlisted Shares

Pharmeasy Unlisted Shares

BUY AT INR 8.72

1/5

Key Indicators

KEY INDICATORS
2023
FACE VALUE/SHARE
1.0
BOOK VALUE/SHARE
4.0
PRICE TO EARNING (PE)
-1.1
PRICE/SALES
0.9
PRICE/BOOK
2.4
OUTSTANDING SHARES (Million)
6142.0
MARKET CAP(Rs.Million)
58042.0
DEBT/EQUITY
2.4
DIVIDEND/SHARE
0.0
DIVIDEND % (ON CMP)
0.0%
RETURN ON TOTAL ASSETS
-63.0%
RETURN ON EQUITY
-213.5%
ROWC
-28.7%

* Ratio is calculated based on latest financial & current share price.

About The Company

API Holdings Limited (Pharmeasy), as per its annual filings, is engaged in the business of undertaking and/or arranging or syndicating all types of business relating to the financing of industry or corporates like logistic and IT sectors. Further, during the year under review, the company had transferred its businesses of wholesale and distribution of drugs (including pharmaceutical products, medical devices, and OTC drugs) and ownership of technology and intellectual property for developing e-commerce platforms including marketplaces for facilitating the sale of pharmaceutical, medical devices, and OTC drugs to its wholly-owned subsidiaries through a slump sale on a going concern basis.
Read More

Pricing Trend

Financials

Revenue Growth %

EBDITA Margin %

EPS Growth %

Profit & Loss Summary

(All Amount in INR Millions)

PROFIT & LOSS
2023
2022
2021
2020
PROFIT & LOSS
2023
2022
REVENUE
66997
57810
23607
7374
REVENUE
66997
57810
EXPENSE
80651
80745
29046
10537
EXPENSE
80651
80745
EBDITA
-13654
-23457
-5439
-3163
EBDITA
-13654
-23457
OTHER COST
38312
-8438
763
307
OTHER COST
38312
-8438
PBT
-51966
-39714
-6203
-3470
PBT
-51966
-39714
Income Tax
152
217
211
-117
Income Tax
152
217
PAT
-52118
-39932
-6413
-3353
PAT
-52118
-39932
OTHER INCOME/EXP.
92
-345
51
1
OTHER INCOME/EXP.
92
-345
INCOME (NET OF TAXES)
-52026
-40277
-6363
-3352
INCOME (NET OF TAXES)
-52026
-40277
OUTSTANDING SHARE
6142
5531
2387
2387
OUTSTANDING SHARE
6142
5531
EPS ( Rs/share)
-8.5
-7.3
-2.7
-1.5
EPS ( Rs/share)
-8.5
-7.3

Balance Sheet

(All Amount in INR Millions)

BALANCE SHEET
2023
2022
2021
2020
BALANCE SHEET
2023
2022
CASH & CASH EQUIVALENT
1936
3292
3232
585
CASH & CASH EQUIVALENT
1936
3292
NON CURRENT ASSET
57216
88961
35872
968
NON CURRENT ASSET
57216
88961
CURRENT ASSET
23412
21730
9948
4173
CURRENT ASSET
23412
21730
TOTAL ASSET
82564
113983
49053
5725
TOTAL ASSET
82564
113983
EQUITY SHARE CAPITAL
6142
6142
256
0
EQUITY SHARE CAPITAL
6142
6142
RESERVES
18227
64083
35556
2462
RESERVES
18227
64083
TOTAL EQUITY
24369
70225
35812
2462
TOTAL EQUITY
24369
70225
NON CURRENT LIABILITY
34963
6142
3480
1987
NON CURRENT LIABILITY
34963
6142
CURRENT LIABILITY
23232
37616
9762
1275
CURRENT LIABILITY
23232
37616
TOTAL LIABILITIES
58195
43758
13242
3262
TOTAL LIABILITIES
58195
43758
TOTAL EQUITY & LIABILITY
82564
113983
49053
5725
TOTAL EQUITY & LIABILITY
82564
113983

Cash Flow Summary

(All Amount in INR Millions)

CASH FLOW
2023
2022
2021
2020
CASH FLOW
2023
2022
OPERATING ACTIVITY
-7442
-25894
-8137
-4453
OPERATING ACTIVITY
-7442
-25894
INVESTING ACTIVITY
-723
-57892
45
-1903
INVESTING ACTIVITY
-723
-57892
FINANCING ACTIVITY
8535
83054
10190
6296
FINANCING ACTIVITY
8535
83054
NET CASH FLOW
370
-732
2098
-60
NET CASH FLOW
370
-732

Shareholders

Shareholders
Naspers Ventures
Macritchie Investments Pte Ltd
TPQ Growth V Markets Pte Ltd
Evermed Holdings Pte Ltd
Surbhi Singh
Dr Velumani A
Cdpq Private Equity Asia Pte. Ltd
Timf Holdings
Bessemer India Capital Holdings II Ltd
All Others
%
13.2
11.9
7.3
6.5
6.1
5.5
5.1
3.8
3.8
36.8

Registered Address

Management

Siddharth Shah
CEO & Managing Director
Yatharth Bhargova
Chief Financial Officer
Drashti Shah
Company Secretary

Annual Reports

Quarterly Reports

NEWS

The Economic Times
Goldman Sachs likely to invest Rs 2,700 crore in PharmEasy parent
LIVE Mint
Pharmeasy in talks with PE firms to raise $250 mn debt
Moneycontrol
PharmEasy wins CNBC-TV18’s IBLA Young Turk of the Year Award
LIVE Mint
Aamir Khan is PharmEasy's brand ambassador
newss
IPOs to watch out for once the primary market starts buzzing
The Economic Times
PharmEasy not in pink of health, shares drop 50% in unlisted market
Moneycontrol
An unexciting start for Thyrocare-PharmEasy combine
The Economic Times
PharmEasy parent company gets Sebi nod for Rs 6,250-cr public offer
Moneycontrol
SEBI gives approval to three more IPOs, including PharmEasy
The Economic Times
PharmEasy may have to rework IPO valuation as street mood swings
31
After chemists' body, traders' body CAIT urges SEBI to reject PharmEasy's IPO request
28
Traders' body approaches SEBI against PharmEasy IPO plans
Moneycontrol
PharmEasy parent API Holdings files DRHP for IPO
youtube
Pharmeasy's intuitive commercials, making pharmaceutical purchases as seamless as possible.
FE
PharmEasy valued at $5.6 billion in pre-IPO round
Moneycontrol
PharmEasy raises $350 million in pre-IPO round: Report
The Economic Times
PharmEasy in talks to raise upto $300 million, valuation may drop by half
The Economic Times
PharmEasy pulls out market listing plan
The Economic Times
PharmEasy Floats Rights Issue to Raise ₹750 crore
Moneycontrol
PharmEasy’s annus horribilis may get worse before it gets better
vc
PharmEasy’s Parent Raises Debt Funding
Entrepreneur.India
How Pharmeasy Founders Changed the Face of Pharmacy
The Economic Times
Exclusive | Not selling Thyrocare, will cut cash burn: PharmEasy founders to board
66
PharmEasy’s parent API Holdings postpones IPO citing market conditions
Bizz Buzz
PharmEasy FY22 loss widens to Rs 2,700 crore
drive news
Teamask backed healthtech startup pharmeasy latest to layoff employees
drive news
Online Pharmacy Market 2023 Growth Opportunities and Future Outlook
LIVE Mint
Pharmeasy charts turnaround, turns cash flow positive Apr
Inventiva
PharmEasy’s Covenant Violation Tests Goldman Sachs’ Patience; Relations Strained?
28
Pharmeasy faces backlash over pharmacist recommending herbal product
INC42
PharmEasy Appoints Avendus Capital For Next Funding Round
The Economic Times
PharmEasy logs first ebitda profit of Rs 14 crore in April, restarts funding talks
The Economic Times
PharmEasy plans Rs 2,400-crore rights issue at 90% discount to repay loan
LIVE Mint
PharmEasy appoints Avendus to help raise $100mn capital
newss
Janus Henderson cuts PharmEasy valuation for 2nd time to $2.7 bn
drive news
PharmEasy breaches Goldman Sachs loan's covenant: Report
Inventiva
PharmEasy Aims for Rs 3,500 Crore Investment Through Right Issue
yourstory
PHARMEASY'S PARENT APPROVES RESOLUTION TO BOOST AUTHORISED SHARE CAPITAL
today
Manipal Group offers to inject Rs 1,000 cr in PharmEasy owner API Holdings
Inventiva
Ambitious Expansion: PharmEasy Aims for Rs 3,500 Crore Investment Through Right Issue
The Economic Times
PharmEasy CEO on 90% drop in share price: ‘Not a valuation cut but a chance to reward shareholders’
yourstory
PHARMEASY PARENT API HOLDINGS CLOCKS RS 60 CR EBITDA IN H1 FY24
The Economic Times
1mg pips PharmEasy in market share; what’s behind PayU’s new business forays?
INC42
PharmEasy Biggest Underperformer In Prosus’ India Portfolio In H1 FY24
66
PharmEasy’s scale crosses Rs 6,600 Cr in FY23; losses down 16%
Business Standard
Pharmeasy FY23 losses widen 31%, revenue increases 16% to Rs 6,644 cr
yourstory
CCI clears Ranjan Pai's proposal to acquire stake in PharmEasy
28
PharmEasy raises $216 million at a 90% lower valuation from peak
yourstory
PharmEasy raises $216M amid 90% valuation drop
Load More

NEWS

Pre-IPO market in tizzy as SEBI flags 200-investor cap; merchant bankers look at workarounds
NSE bonus issue: How to buy and sell unlisted shares?
MCA tweaks rules; large unlisted private firms have to issue shares in demat forms
Stockify broadens horizons with Mutual funds and dematerialization of shares
Piyush Goyal: Had an engaging interaction with leading business leaders in UAE
Three IPL teams looking to unlock value by public listing, raising PE funds
Unlisted companies may face tough disclosure rules
Stockify Fintech reiterates its vow to help HNIs diversify their stock portfolio
Stockify announces single-window online service to buy unlisted equities
Stockify expands global reach with participation at Dubai Fintech Summit
Stockify offers safe, curated and verified Unlisted or Pre-IPO shares to Indians and NRIs
Back Should retail investors pick IPO shares in pre-market? Key highlights
Unlisted stocks slump as dull listings, IPOs on hold hit sentiment
Why Are Pre-IPO Startup Stocks Bleeding In The Unlisted Market?
Confused About Investing In Unlisted Shares?
Can I buy unlisted shares using my Zerodha demat account?
Unlisted Security : Overview, Types, Risks
India IPO pipeline to continue in 2023 despite global uncertainty
Stockify announces single-window online service to buy unlisted equities
Serum Institute, Byju's, NSE among India's top 10 unlisted companies
Budget 2023: What are the pre-budget expectations for unlisted markets?
Should you invest in unlisted equities during a bull run
Stockify Wealth rechristened Stockify Fintech; To help HNIs diversify their stock portfolio
Budget 2023: After surcharge cap, PE/VCs seek LTCG parity on both unlisted and listed shares
Are You Investing In Unlisted Shares? Here’s The Process And Tax Compliances
Norway wealth fund to consider investing in unlisted equities
Should investors blindly follow the trend and invest in unlisted shares?
Load More

VIDEO NEWS

Polymatech: Update On New Manufacturing Unit, Expansion & More
Unlisted companies may face tough disclosure rules
Load More

Latest Articles From The Experts

PharmEasy Secures $216 Million Funding Amidst 90% Valuation Decline

PharmEasy Raises $216M Amid 90% Valuation Drop: Turning Point for Online Pharmacies

CCI Gives Nod To Ranjan Pai’s Investment in PharmEasy: Rs 3,500 crore Rights issue

PharmEasy’s scale crosses Rs 6,600 Cr in FY23; losses down 16%, what does the future look like?

PharmEasy Names Yatharth Bhargova As Its New CFO

LOAD MORE

About PharmEasy Unlisted Shares (API Holdings Ltd.)

India’s digital consumer healthcare app, PharmEasy is referred to as a super app, offering customers on-demand access to home delivery for a comprehensive range of prescriptions and OTC pharmaceuticals. The company provides consumer healthcare products, information, consultations, and diagnostics tests from renowned laboratories. The company has collaborated with trusted doctors and registered in-store pharmacies. Incorporated in 2015, PharmEasy is currently have more than 25 million users. Moreover, with a market capitalization of approximately ₹300 crores, PharmEasy unlisted shares are presently a whizz among investors and financial advisors.

Established by Dharmil Seth and Dr Dhaval Shah, PharmEasy serves every habitable zip code. The authorised share capital of the company is Rs. 1031.08 Cr and the total paid up capital is Rs. 619.69 Cr. The initial idea of the company was to give end users an online pharmacy, but with the inclusion of consultation from trusted doctors and diagnostic tests from renowned laboratories, the application turned out to be quintessential. Furthermore, the company closed a revenue of ₹57,288.21 crores in the fiscal year 2022 opposed to Rs. 2,335 crores in 2021.

 

PharmEasy Unlisted Share Price Overview

Ebbs and flow is a part of every company and in the previous years, almost every firm hit  its all-time low, and so was PharmEasy. However, India’s largest digital healthcare platform boasts the potential to overcome its low. PharmEasy share price experienced a hike during November and December of 2021. After this year, the share price of the company started declining and reached a range varying between ₹30 – ₹40 per share price, which is now ₹22. Additionally, with over 2.4 million transacting consumers, PharmEasy saw a 2.5X  more operating revenue last year.

Despite the growth in profitability, PharmEasy share price has another take in the market. Pharmacy’s unlisted share price witnessed a decline of Rs. 22 in April 2023 and fell to Rs. 12 per equity share in October 2023.  The main reason behind this is negative cash flow and EBITDA (Earnings before interest, taxes, depreciation, and amortisation). Another reason behind it was the setback was the disrupted IPO market. 

Total no. of shares available 10000
Face Value per share ₹ 1 Per Equity Share
ISIN INE0DJ201029
Lot Size 500 Shares
Current Price per share ₹ 12.3 per Equity Share

 

PharmEasy received its first funding in the year 2016 and joined hands with Ascent Health and five other firms to form the most effective digital healthcare platform in India – API Holdings. Presently, the company has a face value of ₹ 1 per equity share and comprising a lot size of 150 unlisted shares.

 

Why Buy PharmEasy Unlisted Shares?

PharmEasy emerged as the most prominent name in the industry after its merger in 2020. With API Holdings as the parent company, PharmEasy is determined to show a staging growth rate, and investors are anticipating nothing less from the firm. Its parent company witnessed a total income which was more than double to $714 million in the fiscal year 2022. Moreover, PharmEasy share price today is  ₹22 per share. Though the PharmEasy stock price witnessed a low in the last few months, the data below clearly depicts that investors are not ready to sell their PharmEasy unlisted shares, further indicating their belief in the growth.

 

Pharmeasy Infographic

Apart from the great face & brand value, and investor’s belief, another reason for investing in PharmEasy is the stunning revenue generated by the company. Look at the company’s data given below:

 

From the above data, the growth of PharmEasy unlisted share price can be clearly anticipated to go up. Further, reports suggest that the platform expects to raise $200 million from its investors and revenue with an annual rate of 18.1% till the end of 2023. Thus, if you want to invest and earn, now is the time! PharmEasy unlisted shares are currently one of the best options for your investment portfolio.

In 2023, PharmEasy made developmental changes and took steps to increase its profitability share in the market. It has significantly reduced its marketing & growth expense from 7.9% to 3.3% of revenue in 2023. As a result, the company’s total marketing expenses fell to Rs. 201 crores.  Moving to its EBITDA (Earnings before interest, taxes, depreciation, and amortisation) margin, the rates improved from -13.6% to -8.4% in FY 2023. 

PharmEasy strategically focuses on increasing its share of margin accretive private labels during the period of FY 2022-23. Additionally, it developed a focus on investing to scale up its cross-sell capabilities to get high-margin services for customers. For the fiscal year 2023, almost 50 lakh customers, which constitutes 13.8% of the total PharmEasy consumer base, avail their diagnostic services. 

How To Apply For PharmEasy Unlisted Shares Online?

Buying PharmEasy unlisted shares is pretty easy, especially with Stockify. We are here with an ensemble of details such as Key Performance Indicators, revenue growth, EBITDA margin reports, EPS growth, etc. Moreover, the expert stock brokers at Stockify constantly keep track of the trends and changes in the PharmEasy unlisted shares price, and update prices as per the market fluctuation daily.

 

PharmEasy stock price is currently the talk of the town. Analyse and compare the key indicators, figure out your requirements and rely on our experts to guide you throughout the PharmEasy unlisted shares buying process. We will take care of everything – from guidance to documentation.

 

Check PharmEasy Unlisted Share Price Today at Stockify

PharmEasy company share price is updated every day at Stockify. Our experts stay updated with stock market trends and keep a close eye on PharmEasy stock price fluctuations and immediately update prices as per the market trends on a daily basis. If you are interested in buying PharEasy Unlisted Shares, connect with us and stay tuned with our prices.

 

You can subscribe to our newsletter to get regular updates regarding PharmEasy share price, market trends, and other indicators which assist in determining whether or not a share is beneficial for your portfolio. PharmEasy unlisted share price India is ₹22.

 

Check Out Prices Of Other Unlisted Shares On Stockify

For those who want to cope with market fluctuation, portfolio diversification is paramount for them. Diversification is a vital way to minimise the blow that hits while the market goes down. Stockify brings a list of unlisted shares from top-rated Pre-IPO companies at authentic prices. Apart from buying and selling PharmEasy unlisted shares, you can also check the best unlisted shares in India. We bring you unlisted shares from all the sectors – IT, energy, healthcare, insurance, technology, finance, manufacturing, and many more. Take a look at the PharmEasy share price today and also glance up other unlisted shares hosted by Stockify, as specified below:

 

Reliance Retail, boAT Unlisted Shares, Chennai Super Kings, Anglo-French Drugs & Industries, Hexaware Technologies Ltd, Five Star Business Finance Ltd Unlisted Shares, Fincare Small Finance Bank Ltd Unlisted Shares, Arohan Financial Services Unlisted Shares, Utkarsh Coreinvest Ltd Unlisted Shares, Fino Paytech Ltd Unlisted Shares, Hero Fincorp Ltd Unlisted Shares, National Stock Exchange Ltd Nse Unlisted Shares, National Commodity Derivatives Exchange Ltd Ncdex Unlisted Shares, MetroPolitan Stock Exchange MSEI Unlisted Shares, Capital, Small Finance Bank Ltd Unlisted Shares, and Motilal Oswal Home Finance Ltd Unlisted Shares.

 

Login To Buy PharmEasy Unlisted Shares Today!

 

 

 

Read More

FAQ On PharmEasy Unlisted Shares

Due to past performance and potential to grow, investment in API Holdings Ltd(PharmEasy) unlisted shares is a wise choice. At Stockify, you can easily buy and sell unlisted shares of API Holdings Ltd(PharmEasy). You just need to connect with our expert share brokers, and they will help you throughout the process.
If you are wondering how to sell API Holdings Ltd(PharmEasy) shares online, just fill out basic details in the form and our experts will get back to you. Right from the initial deal to the final transfer of shares, our unlisted share brokers will help. Check out the list of the best unlisted shares in India or reach out to reputed unlisted share dealers online.
SEBI has recently reduced the lock-in period from 1 year to 6 months. There is a minimum lock-in period of 6 months from the date of purchase of unlisted shares. However, these shares can be freely transferable before listing in NSE/BSE. Connect with unlisted share experts at +91-80 4113 3935/+91-7353266646
In the recent, unlisted share market in India is spreading its wings and becoming quite big. Some highly recognized companies like Reliance, HDB finance and even the National Stock Exchange are trading unlisted stocks. At Stockify, we allow you to buy and sell any number of API Holdings Ltd(PharmEasy) unlisted shares as per your budget or needs. Customise your unlisted share trading experience.
Yes, this is 100% legal and safe to buy unlisted shares of API Holdings Ltd(PharmEasy). However, this is applicable when you buy API Holdings Ltd(PharmEasy) unlisted shares from reliable and known unlisted share dealers. You can request a quote or trade online at Stockify, we are ready to assist you.
There is no difference between the tax of unlisted and listed shares. Short-term capital gain taxes are usually paid on the profit of shares held for one year or less. A rate of 15% will be charged as STCG tax and surcharges will be added based on the period of your holding. Buying unlisted shares in bulk? Talk to our experts to learn more.
Applicability of Taxes on API Holdings Ltd(PharmEasy) unlisted shares once it is listed?
The credit transfer process is also the same for both listed and unlisted stocks. Once the share is transferred it will be reflected in your depositary/Demat account NSDL/CDSL. You can also check it online by logging into the NSDL/CDSL account.
At Stockify, we have simplified the whole process of unlisted share trading. A basic KYC is required for investing in unlisted stocks. For KYC verification, you will need to show Adhar | PAN | Demat CML For NRI |PAN|DEMAT CML| NRO Bank statement. Want to know more about how to buy unlisted shares in India? Connect with expert share brokers today!
There are multiple factors such as Demand/Supply of shares, valuation of the companies & multiple other factors that affect the returns on any unlisted shares. For eg. Investment of 1 Lakh in CSK shares in 2019 is worth 20 lakhs today in 2022 (20x returns in just 3 year). The return on investment of unlisted shares also varies depending on the period of holding. Estimating a return on unlisted shares requires in-depth knowledge and understanding of the industry. So, you can connect with our unlisted share experts to get a greater share of profit
Due to past performance and potential to grow, investment in API Holdings Ltd(PharmEasy) unlisted shares is a wise choice. At Stockify, you can easily buy and sell unlisted shares of API Holdings Ltd(PharmEasy). You just need to connect with our expert share brokers, and they will help you throughout the process.
Yes, selling and buying PharmEasy unlisted shares is ethical and legal in India. If you are interested in purchasing, connect with the experts at Stockify today, consult the best options for your portfolio and simply buy them with us for hassle-free trading!
Yes, both online and offline DIS is available for PharmEasy unlisted shares. Since Stockify is an online unlisted shares broker, you can simply fill out the online DIS for PharmEasy unlisted shares.
You can buy PharmEasy unlisted shares easily from Stockify. Check out the PharmEasy share price today, consult our experts, spot your requirements and hit “buy”!
SHARE
Join Stockify's WhatsApp Community
Stockify Fintech Pvt. Ltd.
Stockify Fintech Pvt. Ltd

Provide Email And Download!

Stockify Fintech Pvt. Ltd

Provide Email And Download!

Stockify Fintech Pvt. Ltd.

Haven't found what you're looking for?
Speak to an expert.
Book an appointment by clicking on the link below.

Piyush Jhunjhunwala
Piyush Jhunjhunwala
CA, CPA, Ex. PepsiCo, Reckitt, Coty
CEO & Founder
Dubai, UAE.
Rahul Khatuwala
Rahul Khatuwala
Ex. Wipro & Finaco Founder
Co-Founder
Bangalore, India.